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Since the middle 1990s biologics have been available for
rheumatic diseases. The initial experiments showed effi-
cacy for symptoms and signs but concern was expressed
about tachyphylaxis and absence of a true DMARD effect.
Combining the antibodies with methotrexate answered
some of these criticisms and since that time the number
of agents available for rheumatoid arthritis, psoriatic
arthritis and spondyloarthropathy has grown.
It is clear these agents work, what is less clear is how
they should be used to produce optimum cost benefit.
The ever expanding market has attracted a large number
of pharmaceutical players to this area and this shows no
sign of abating. Also there are number of new drugs
including oral synthetic DMARDs becoming available.
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